WHO surveillance confirms susceptibility of influenza viruses to antivirals
The vast majority of seasonal and zoonotic influenza viruses tested remained susceptible to neuraminidase inhibitors (NAIs) and the polymerase inhibitor, baloxavir marboxil.
Adult Respiratory Vaccination Delivers Up to $12 in Societal Value for Every $1 Spent, Analysis Finds
Benefit-cost modeling estimated $22B annual spend produces $101B-$241B net benefits, preventing ~18,500 deaths and 300,000 hospitalizations in a single year.
Beyond childhood: why lifelong vaccination is a frontline defence against chronic disease
Guest article by the World Federation of Public Health Associations (WFPHA)
mRNA-based influenza vaccine expands the B cell response breadth in humans
These findings reveal a key role for persistent germinal center responses in broadening the repertoire of vaccine-induced antibodies.
Recombinant Influenza Vaccine and Influenza Outbreaks in US Nursing Homes: Results From a Pragmatic Cluster-Randomized Clinical Trial
These findings suggest that recombinant influenza vaccines may provide clinically meaningful facility-level benefits in long-term care settings during seasons with substantial influenza circulation.
High-dose vs standard-dose influenza vaccine in heart failure: the FLUNITY-HD pooled analysis
The results of prior randomized trials investigating the potential role of influenza vaccination in preventing severe clinical events in various HF populations have been mixed.
Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial
In adults aged 50 years or older, aQIVc was non-inferior and superior to aQIV for all four influenza strains and non-inferiority criteria for aQIVc versus QIVr were met for A/H1N1 and both B strains, but not A/H3N2.
Emergence and spread of NA-I223V and NA-S247N double-mutant A(H1N1)pdm09 influenza viruses with reduced oseltamivir susceptibility in the Netherlands and beyond, 2023 to 2026
These findings underscore the need for ongoing genomic and phenotypic monitoring of antiviral susceptibility.